GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GW823093 placebo capsuleDrug: GW823093 15mgDrug: GW823093 30mg
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00372957
- Locations
GSK Investigational Site
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influsplit SSW® 2005/2006
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00372255
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GW642444Other: Placebo
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT00372112
- Locations
- 🇷🇴
GSK Investigational Site, Iasi, Romania
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
Phase 1
Completed
- Conditions
- Neoplasms, Breast
- Interventions
- Drug: GW572016 oral tablets
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00371488
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
Phase 2
Completed
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: Lapatinib oral tabletsDrug: Placebo
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2010-04-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 107
- Registration Number
- NCT00371566
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
Phase 3
Completed
- Conditions
- Malaria, Falciparum
- Interventions
- Drug: chlorproguanil-dapsone-artesunateDrug: chlorproguanil-dapsone
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 900
- Registration Number
- NCT00371735
- Locations
- 🇳🇬
GSK Investigational Site, Maiduguri, Nigeria
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
Phase 2
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GW823093C ADrug: GW823093C BDrug: GW823093C C
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 159
- Registration Number
- NCT00370942
- Locations
GSK Investigational Site
Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00370591
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, Lancashire, United Kingdom
Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00370435
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
Phase 3
Completed
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- Drug: PlaceboDrug: eltrombopag
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT00370331
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath